Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy for Neuro-oncology.
Majd NK, Dasgupta PR, de Groot JF. Majd NK, et al. Among authors: de groot jf. Adv Exp Med Biol. 2021;1342:233-258. doi: 10.1007/978-3-030-79308-1_7. Adv Exp Med Biol. 2021. PMID: 34972967 Review.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Cloughesy TF, et al. Among authors: de groot jf. Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11. Nat Med. 2019. PMID: 30742122 Free PMC article. Clinical Trial.
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Weathers SP, et al. Among authors: de groot jf. Clin Cancer Res. 2020 Jul 15;26(14):3565-3577. doi: 10.1158/1078-0432.CCR-20-0176. Epub 2020 Apr 16. Clin Cancer Res. 2020. PMID: 32299815 Free PMC article. Clinical Trial.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Wen PY, et al. Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106. Neuro Oncol. 2020. PMID: 32328653 Free PMC article. Review.
A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram.
Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger AB. Ferguson SD, et al. Among authors: de groot jf. Neurooncol Adv. 2020 Oct 31;3(1):vdaa146. doi: 10.1093/noajnl/vdaa146. eCollection 2021 Jan-Dec. Neurooncol Adv. 2020. PMID: 33426529 Free PMC article.
The promise of DNA damage response inhibitors for the treatment of glioblastoma.
Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. Majd NK, et al. Among authors: de groot jf. Neurooncol Adv. 2021 Feb 4;3(1):vdab015. doi: 10.1093/noajnl/vdab015. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 33738447 Free PMC article. Review.
Neurologic Toxicities of Immunotherapy.
Harrison RA, Majd NK, Tummala S, de Groot JF. Harrison RA, et al. Among authors: de groot jf. Adv Exp Med Biol. 2021;1342:417-429. doi: 10.1007/978-3-030-79308-1_18. Adv Exp Med Biol. 2021. PMID: 34972978
199 results